CorMedix Announces Interim Analysis & Clinical Update For Phase II Study Of CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001...

doctor oz